Experts issue guidance on lung disease tied to rheumatoid arthritis
An international consensus statement gives clinicians advice on screening, monitoring and treating RA-associated interstitial lung disease.
By Priya Raghavan · Science Reporter
2 min read
An international group of specialists has issued new recommendations for finding and caring for a serious lung complication in people with rheumatoid arthritis. National Jewish Health said the guidance is meant to help doctors identify rheumatoid arthritis-associated interstitial lung disease earlier and manage patients more consistently.
The consensus statement was published in The Lancet Respiratory Medicine. It addresses screening, diagnosis, monitoring and treatment for RA-associated interstitial lung disease, often called RA-ILD.
Rheumatoid arthritis is widely associated with joint pain and inflammation, but National Jewish Health said the disease also can involve the lungs. RA-ILD causes scarring and inflammation in lung tissue, which can make breathing harder and reduce quality of life.
Joshua Solomon, director of interstitial lung disease at National Jewish Health and lead author of the statement, said rheumatoid arthritis can affect a person's health beyond the joints. He said the recommendations give clinicians practical advice on spotting lung disease sooner, following patients more effectively and deciding when treatment may be needed.
Why guidance was needed
National Jewish Health said doctors have lacked broad agreement on several parts of RA-ILD care, including which rheumatoid arthritis patients should be screened, how often patients should be checked after diagnosis and when treatment should start. The expert panel developed consensus recommendations to guide decisions in those areas.
The specialists reviewed available research and identified risk factors linked to a higher chance of developing RA-ILD, according to National Jewish Health. The statement also outlines ways to screen rheumatoid arthritis patients considered at higher risk and approaches for watching whether lung disease is getting worse.
The guidance includes treatment considerations, though National Jewish Health said the recommendations are intended for clinical situations where strong trial data remain limited. The publication does not replace clinical judgment, but it gives doctors a shared framework for decisions that often involve uncertainty.
Team care emphasized
The statement calls for coordinated care involving rheumatologists, pulmonologists and other specialists, according to National Jewish Health. That approach reflects the overlap between autoimmune disease management and lung disease care in patients with RA-ILD.
Researchers hope the recommendations will lead to earlier diagnosis, more uniform monitoring and better outcomes for people with lung disease related to rheumatoid arthritis, National Jewish Health said. The guidance also signals growing attention to complications of rheumatoid arthritis that occur outside the joints.
The publication is listed as: Joshua J. Solomon and colleagues, “Rheumatoid arthritis-associated interstitial lung disease: screening, diagnosis, and treatment—an expert group consensus statement,” in The Lancet Respiratory Medicine, 2026.
This story draws on original reporting from Medical Xpress.